1. Introduction
Calcific Aortic Stenosis is the most common cause of aortic valve disease in developed countries. This condition increases in prevalence with the advancing age of the U.S. population, afflicting 2-3 % by age 65 [1]. Aortic valve replacement is the number one indication for surgical valve replacement in the United States and in Europe. The natural history of severe symptomatic aortic stenosis is associated with 50% mortality within 5 years [2]. Bicuspid aortic valve disease is the most common congenital heart abnormality and it is the most common phenotype of calcific aortic stenosis. The bicuspid aortic valve (BAV) is the most common congenital cardiac anomaly, having a prevalence of 0.9 to 1.37% in the general population [3]. Understanding the cellular mechanisms of tricuspid versus bicuspid aortic valve lesions will provide further understanding the mechanisms of this disease. Currently, there are three fundamental mechanisms defined in the development of aortic valve disease: 1) oxidative stress via traditional cardiovascular risk factors [4-8,6, 7, 9-12], 2) cellular proliferation [13] and 3) osteoblastogenesis in the end stage disease process [14, 15]. Previously, the Wnt/Lrp5 signaling pathway has been identified as a signaling mechanism for cardiovascular calcification [5, 16, 17]. The corollaries necessary to define a tissue stem cell niche: 1) physical architecture of the endothelial cells signaling to the adjacent subendothelial cells: the valve interstitial cell along the valve fibrosa. 2) defining the oxidative-mechanical stress gradient necessary to activate Wnt3a/Lrp5 in this tissue stem niche to induce disease. Recently, the mechanisms of oxidative stress have been identified in the development of calcific aortic valve disease. This chapter will outline the factors important in the role of calcific aortic valve disease.
2. The role of lipids in vascular and valvular disease
The role of lipids in vascular atherosclerosis has been defined in the literature for years. Atherosclerosis is a complex multifactorial process which produces a lesion composed of lipids [18, 19], macrophages [20], and proliferating smooth muscle cells [21] apoptosis [22] and extracellular bone matrix production [23] in the vascular wall [24, 25]. The activation of these cellular processes is regulated by a number of pathways. Integrins provide an important role in the regulation of cellular adhesion in atherosclerosis [26]. Another critical regulator of vascular endothelial biology is nitric oxide (NO) [27, 28]. Cholesterol-rich LDL also has a critical role in the onset and further progression of the atherosclerotic lesion via an inactivation of endothelial nitric oxide synthase (eNOS) [22, 29-31] contributing to an abnormal oxidation state within the vessel. In this inflammatory environment, growth factors and cytokines are secreted to induce vascular smooth cell proliferation and recruitment of macrophage cells [32-37] which are important in the development of the atherosclerotic plaque lesion.
Recently, similar risk factors for calcific aortic valve disease have recently been described including male gender, hypertension, elevated levels of LDL, and smoking [38, 39] which mimic those that promote the development of vascular atherosclerosis. Surgical pathological studies have demonstrated the presence of LDL and atherosclerosis in calcified valves, demonstrating similarities between the genesis of valvular and vascular disease and suggesting a common cellular mechanism [40, 41]. Patients who have the diagnosis of familial hypercholesterolemia develop aggressive peripheral vascular disease, coronary artery disease, as well as aortic valve lesions which calcify with age [10, 42]. Rajamannan et al, have shown that the development of atherosclerosis occurs in the aortic valve in a patient with Familial Hypercholesterolemia with the Low density lipoprotein receptor mutation [10]. The atherosclerosis develops along the aortic surface of the aortic valve and in the lumen of the left circumflex artery [10]. This provides the first index case of atherosclerotic aortic valve disease in this patient population. Studies have confirmed in experimental hypercholesterolemia that both atherosclerosis and osteoblast markers are present in the aortic valves [4, 6, 13]. This background provides the foundation for studying valve calcification in an experimental atherosclerotic
3. Aortic valve calcification
The presence of calcification in the aortic valve is responsible for valve stenosis. Severe aortic stenosis can result in symptomatic chest pain, as well as syncope and congestive heart failure in patients with severe aortic valve stenosis. For years, aortic valve stenosis was thought to be a degenerative process. However, the pathologic lesion of calcified aortic valves demonstrate indicate the presence of complex calcification in these tissues. Furthermore, there are a growing number of descriptive studies delineating the presence of bone formation in the aortic valve [15, 43, 44].
Until recently the etiology of valvular heart disease has been thought to be a degenerative process related to the passive accumulation of calcium binding to the surface of the valve leaflet. Recent descriptive studies have demonstrated the critical features of aortic valve calcification, including osteoblast expression, cell proliferation and atherosclerosis [6, 14, 15, 45] and mitral valve degeneration, glycosaminglycan accumulation, proteoglycan expression, and abnormal collagen expression [46-49]. These studies define the biochemical and histological characterization of these valve lesions. We and others, have also shown that specific bone cell phenotypes are present in calcifying valve specimens in human specimens [16, 50]. These data provide the evidence that the aortic valve calcification follows the spectrum of bone formation in calcifying tissues.
4. The role of Lrp5/beta-catenin activation in cardiovascular calcification and osteoblast bone formation: Connection with the bone axis
Bone and cartilage are major tissues in the vertebrate skeletal system, which is primarily composed of three cell types: osteoblasts, chrondrocytes, and osteoclasts. In the developing embryo, osteoblast and chrondrocytes, both differentiate from common mesenchymal progenitors in situ, where as osteoclasts are of hematopoietic origin and brought in later by invading blood vessels. Osteoblast differentiation and maturation lead to bone formation controlled by two distinct mechanisms: intramembranous and endochondral ossification, both starting from mesenchymal condensations.
To date only two osteoblast-specific transcripts have been identified: 1) Cbfa1 and 2) osteocalcin (OC). The transcription factor Cbfa1 [51] has all the attributes of a ‘master gene’ differentiation factor for the osteoblast lineage and bone matrix gene expression. During embryonic development, Cbfa1 expression precedes osteoblast differentiation and is restricted to mesenchymal cells destined to become osteoblast. In addition to its critical role in osteoblast commitment and differentiation, Cbfa1 appears to control osteoblast activity, i.e., the rate of bone formation by differentiated osteoblasts [51]. We have shown previously that cholesterol upregulates Cbfa1 gene expression in the aortic valve and atorvastatin decreases the gene expression [6] in an animal model. We have also demonstrated that Sox9 and Cbfa1 are expressed in human degenerative valves removed at the time of surgical valve replacement [16]. The regulatory mechanism of osteoblast differentiation from osteoblast progenitor cells into terminally differentiated cells is via a well orchestrated and well studied pathway which involves initial cellular proliferation events and then synthesis of bone matrix proteins, which requires the actions of specific paracrine/hormonal factors and the activation of the canonical Wntpathway [52].
Genes which code for the bone extracellular matrix proteins in osteoblast cells include alkaline phosphatase (AP), osteopontin (OP), osteocalcin (OC), and bone sialoprotein (BSP). This data supports a potential regulatory mechanism that these matrix proteins play a critical role in the development of biomineralization. To date, many of these markers have been shown to be critical in the extracellular mineralization and bone formation that develops in normal osteoblast differentiation (Fig.5). Dr. Spelsberg and Dr. Rajamannan have extensive experience in osteoblast cell biology and will contribute to the translational studies in the aortic valve involving the differentiation and mineralization [53, 54].
A link between lipids and osteoporosis have been studied extensively [55-60]. These groups have shown in
Our lab (43) and Towler’s laboratory (44) have shown that the Lrp5/Wnt/beta-catenin pathway plays an important role in the development of vascular and valvular calcification. Studies have shown that different mutations in Lrp5, an LDL receptor related protein; develop a high bone mass phenotype and an osteoporotic phenotype (45, 46). In the presence of the palmitoylation of Wnt an active beta-catenin accumulates in the cytoplasm, presumably in a signaling capacity, and eventually translocates to the nucleus via binding to nucleoporins [64], where it can interacts with LEF-1/TCFs in an inactive transcription complex [65, 66], The Wnt/Lrp5/frizzled complex turns on downstream components such as Dishevelled (Dvl/Dsh) which leads to repression of the glycogen synthase kinase-3 (GSK3) [67]. Inhibition of GSK3 allows beta-catenin to accumulate in the nucleus, interacting with members of the LEF/TCF class of architectural HMG box of transcription factors including Cbfa1 involved in cell differentiation and osteoblast activation [68, 69, 70-72] and Sox 9, a HMG box transcription factor, is required for chondrocyte cell fate determination and marks early chondrocytic differentiation of mesenchymalprogenitors [73].
To determine a potential signaling pathway for the development of aortic valve disease there are numerous pathways which may be implicated in this disease process [50, 74, 75]. Recent evidence suggests that the Wnt pathway regulates the expression of bone mineral markers in cells responsive to the Wnt pathway. Furthermore the Wnt pathway has been shown to be activated by lipids. Therefore we chose to assess this pathway in our model of experimental hypercholesterolemia to determine how lipids may be regulating Lrp5 in the aortic valve. This background outlines the potential for lipids in the regulation of aortic valve mineralization via the canonical Wnt pathway.
5. Echocardiography and Computerized Tomography (CT) evaluation of the development of calcification and stenosis
Currently the non-invasive “gold standard” for the diagnosis of aortic valve stenosis is 2-Dimensional doppler echocardiography. It is the test of choice to quantify the severity of valve stenosis and pressure differential across the aortic valve. There are a increasing number of studies which have demonstrated the utility of calculating the volume of calcium and the rate of progression of the disease process in the aortic valve [76-80]. Confirmation of hemodynamic valve stenosis by echo will provide the degree of valve stenosis using ultrasound techniques4. MicroCT will assess the degree of calcification within the mineralizing tissues.
6. Development of future medical therapies for calcific aortic stenosis
The natural history studies of valvular aortic stenosis as defined by clinical and histopathologic parameters have provided landmark developments towards the understanding of this disease. HMG CoA reductase inhibitors may provide an innovative therapeutic approach by employing both lipid lowering and possibly non-lipid lowering effects to forestall critical stenosis in the aortic valve. Our laboratory has shown that atorvastatin has a number of effects in the aortic valve including: 1) inhibition of foam cell accumulation [6], 2) inhibition of Cbfa1 activation [6], 3) eNOS enzymatic activation [11] and 4) attenuation of Lrp5 receptor activation [81]. Statins have potent LDL lowering effects via inhibition of the rate-limiting step in cholesterol synthesis. There are a number of experimental models which demonstrate the potential for treating the vasculature with statins to inhibit matrix formation [24, 25], cellular proliferation [6] and vascular aneurysm formation [82]. Although valve replacement is the current treatment of choice for severe critical aortic stenosis, future insights into the mechanisms of calcification and its progression may indicate a role for lipid lowering therapy in modifying the rate of progression of stenosis.
There are a growing number of retrospective studies demonstrating that statins may have benefits in slowing the progression of aortic stenosis [83-85]. A recent clinical trial by Cowell et al, demonstrated that high dose atorvastatin did not slow the progression of aortic stenosis in patients [86]. However, the timing of the initiation of the statin therapy was at a later stage of aortic valve disease. A clinical trial in Portugal called RAAVE- Rosuvastatin Affecting Aortic Valve Endothelium demonstrated prospectively that statins slow progression in CAVD in an open label study. In the RAAVE study we found a change in aortic valve area (AVA) in the control group was -0.10±0.09 cm2 per year versus -0.05 ±0.12 cm2 per yearin the Rosuvastatin group (p=0.041). In addition there was an increase in peak aortic valve velocity was +0.24±0.30 m/sec/yr in the control group as compared to the increase in +0.04±0.38 m/sec/yr in the Rosuvastatin group (p=0.007), indicating that in this prospective hypothesis driven study we found by echocardiography a slowing of progression in the aortic valve disease. SALTIRE initiated atorvastatin in patients who had more advanced aortic stenosis as defined by the mean aortic valve area 1.03 cm2 as compared to the average aortic valve area in RAAVE of 1.23 cm2 as the baseline aortic valve area prior to treatment with Rosuvastatin [87]. The investigators of RAAVE hypothesize that the beneficial effect of the statin was secondary to the early initiation of treatment. Furthermore, the SALTIRE investigators recently acknowledged the potential of medical therapies may be found if the treatment of this disease is initiated earlier in the disease process [86]. The studies planned in this application should lead to an important understanding of the molecular and cellular mechanisms of aortic valve disease. Furthermore, the experimental approach will also correlate the development of valve calcium by MicroCT and hemodynamic progression by echocardiography in this important disease process.
The bicuspid aortic valve (BAV) is the most common congenital cardiac anomaly, having a prevalence of 0.9 to 1.37 % in the general population [3]. The natural history of the BAV is progressive stenosis that typically occurs at a faster rate than tricuspid aortic valves requiring earlier surgical intervention in the BAV patients [2, 3]. With the decline of acute rheumatic fever, calcific aortic stenosis has become the most common indication for surgical valve replacement. Despite the high prevalence of aortic stenosis, few studies have investigated the mechanisms responsible for aortic valve disease. The cellular mechanism for the development of this disease is not well known. Previously, we and others have demonstrated that aortic valve calcification is associated with an osteoblast bone-like phenotype [14, 15]. This bone phenotype is regulated by the canonical Wnt pathway in experimental cardiovascular calcification [5, 17]. We have alsoshown that the canonical Wnt/Lrp5 pathway is upregulated in diseased human valves from patients with valvular heart disease [16]. These studies implicate that inhibition of the canonical Wnt pathway provides a therapeutic approach for the treatment of degenerative valvular heart diseases. A recent study [88], discovered that a loss of function mutation in Notch1 was associated with accelerated aortic valve calcification and a number of congenital heart abnormalities. Normal Notch1 receptor functions to inhibit osteoblastogenesis [89, 90]. Evaluation of Notch1 gene and protein expression in human bicuspid calcified valves compared to normal aortic valves removed at the time of surgical valve replacement is shown in Figure 1, Panel A. Notch1 protein expression was decreased in the BAV compared to controls by immunhistochemistry and Western Blot expression Figure 1, Panel B1 and B2, and C. RNA expression by RTPCR indicates a spliced Notch1 receptor in the diseased valves as compared to controls as shown in Figure 1, Panel D. This Notch1 splicing may be the regulatory switch important for the activation of the Wnt pathway and downstream calcification in these diseased valves [5, 17, 90].
Risk factors for the development of calcific aortic valve disease(CAVD) have been elucidated in a number of epidemiologic databases [38]. The risk factors for CAVD are similar to those of vascular atherosclerosis which include: elevated LDL, hypertension, male gender, smoking and increased body mass index [38]. The elucidation of these risk factors have provided the experimental basis for hypercholesterolemia as a method to induce aortic valve disease [4-8. Furthermore, studies have shown that the eNOS-/- mouse is a novel mouse model which develops anatomic bicuspid aortic valves (BAV) [91]. To understand if eNOS-/- mice with the BAV phenotype, develops accelerated stenosis earlier than tricuspid aortic valves via the Lrp5 pathway activation, eNOS-/- mice were given a cholesterol diet versus cholesterol and atorvastatin. The Visual Sonics mouse echocardiography machine was used to screen for the BAV phenotype. Echocardiography hemodynamics was also performed to determine the timing of stenosis in bicuspid vs. tricuspid aortic valves eNOS-/- mice on different diets.
Figure 2 demonstrates the characterization of the eNOS phenotype as defined by histology, RTPCR and echocardiography. In Figure 2, Panel A is the histology for BAV, Figure 2, Panel B is the semi-quantitative RTPCR from the BAV eNOS-/- mice, and echocardiographic data for the bicuspid vs. tricuspid aortic valves Figure 2, Panel C. We measured Notch1, Wnt3a and downstream markers of the canonical Wnt pathway by protein and RNA expression. Notch1 protein was diminished and the RNA expression demonstrates a similar spliced variant with lipid treatments which was not present with the control and atorvastatin treatment. Cholesterol diets increased the members of the canonical Wnt pathway and Atorvastatin diminished these markers significantly (p<0.05).
BAV is a complex model to study the mechanisms of calcification. The importance of cell-cell communication within a stem cell niche is necessary for the development of valvular heart disease. The two corollaries necessary for an adult stem cell niche is to first define the physical architecture of the stem-cell niche and second is to define the gradient of proliferation to differentiation within the stem-cell niche. The endothelial lining cell located along the aortic surface is responsible for the secretion of a growth factors [92]. These cells interact with the subendothelial cells that are resident below the endothelial layer of cells. These cells have been characterized as myofibroblast cells [75, 93, 94].
To test the hypothesis that BAV disease develops secondary to a stem cell niche process, the physical cell-cell communication needed to be established [95]. In the aortic valve the communication for the stem cell niche would be between the aortic valve endothelial cell and the adjacent myofibroblast cell located below the aortic lining endothelial cell. Conditioned media was produced from untreated aortic valve endothelial cells for the microenvironment that activates signaling in the myofibroblast cell. A mitogenic protein (Wnt3a) was isolated from the conditioned media and then tested directly on the responding mesenchymal cell, the cardiac valve myofibroblast [93, 96,95]. This transfer of isolated protein to the adjacent cell was necessary to determine if the cell would proliferate directly in the presence of this protein. This system is appealing because the responding mesenchymal cell is isolated from the anatomic region adjacent and immediately below that of the endothelial cells producing the growth factor activity along the fibrosa surface. Very little is known regarding the characterization of the endothelial cell conditioned media. These experiments test the corollary that the physical architecture described above is necessary for disease development in the aortic valve.
Figure 3 demonstrates the isolation and characterization of the Wnt3a from the conditioned media microenvironment. Figure 3, Panel A, is light microscopy of aortic valve endothelial cells isolated from the aortic surface of the aortic valve. The results of the mitogen assays for fractions eluting from a DEAE- Sephadex column are shown in Figure 3, Panel B. It can be seen that the mitogenic activity appeared as a single peak eluting at approximately 0.25 M NaCl. The material eluting from DEAE- Sephadex was then applied to Sephadex G-100; the results of mitogen assays on fractions eluting from such a gel filtration column are shown in Figure 3, Panel C. It can be seen that under these native, non-denaturing conditions the bulk of the mitogenic activity eluted as a peak corresponding to standard proteins of 30- 40,000 molecular weight. A SDS denaturing protein gel was run on each sample from the eluted proteins and the bulk of activated protein correlated with the protein peak at 46kd as shown in Figure 3, Panel D. The protein size and charge determination is similar to that previously characterized as Wnt3a [97]. This material lost all activity when heated to 100oC for 5 minutes; disulfide bond reduction with dithiothreitol also abolished all mitogenic activity; and treatment with trypsin destroyed all activity, implicating a protein structure.
The second corollary for identifying a stem cell niche is to define the gradient responsible for the proliferation to differentiation process. The main postulate for this corollary stems from the risk factor hypothesis for the development of aortic valve disease. If traditional atherosclerotic risk factors are necessary for the initiation of disease, then these risk factors are responsible for the gradient necessary for the differentiation of myofibroblast cells to become an osteoblast calcifying phenotype [5, 17, 62, 75, 94, 95, 98, 99]. If traditional risk factors are responsible for the development of valvular heart disease, then an oxidative stress mechanism is important for the development of a gradient in this niche.
Nitric oxide is important in terms of the mechanism in adult disease processes and also in the developmental abnormalities such as the bicuspid aortic valve phenotype in the eNOS null mouse. To answer this question of the role of oxidative stress and nitric oxide in the aortic valve, I performed
The proof of principle experiment to test the importance of eNOS enzymatic activity is an overexpression experiment to determine if eNOS is able to inhibit cell proliferation, an early cellular event in the development of aortic stenosis [13]. Experiments were performed to overexpress eNOS to determine if eNOS overexpression in the aortic valve endothelial cells would regulate cell proliferation. The in vitro myofibroblast cells were directly transduced with an eNOS adenoviral gene construct. Thymidine incorporation was measured to test if overexpressing eNOS can inhibit cellular proliferation. Figure 4, Panel A3, eNOS overexpression inhibits the cell proliferation in the oxidized LDL treated cells induced as compared to the LacZ control treated cells.
A key regulator of eNOS function is caveolin-1 which is expressed in aortic valve endothelial cells [9. Caveolin-1 upregulation in the presence of lipids inactivates eNOS enzymatic function and further promotes oxidative stress [100, 101]. Experiments were performed to localize the expression of Caveolin1 and eNOS in the aortic valve endothelial cell caveolae. A well defined mechanism to inactivate eNOS enzymatic activity is functional binding of eNOS with caveolin1 in the presence of lipids [29, 95, 102]. Figure 4, Panel B1, demonstrates that Caveolin-1 is upregulated in the lipid treated cells and decreases with atorvastatin treatment with no change in the eNOS protein expression as shown by Western Blot. Figure 4, Panel B2, demonstrates the ultrastructural evidence by immunogold labeling for eNOS and Caveolin-1 present in the aortic valve endothelial cells in caveolae, similar to previously reported data [9, 11]. This caveolin1 upregulation is indirect evidence in addition to the direct data of a decrease in the enzyme activity, that caveolin-1 may play a similar role in AEC found in the aortic valve similar to the vascular endothelium.
Experiments were performed to determine if Wnt3a secretion changes in the microenvironment of the aortic valve endothelial cells with and without lipids. Figure 4, Panel C, demonstrates that Wnt3a protein concentration in the conditioned media in the presence of LDL with and without Atorvastatin. There is a significant increase in the protein with the lipids and attenuation of this protein secretion with the Atorvastatin treatments. This experiment tests the effects of lipids regulating the development of a “Wnt3a” gradient in the microenvironment. If LDL increases Wnt3a secretion into the conditioned media or the microenvironment of the diseased aortic valve, this further contributes to the activation of the canonical Wnt pathway in the subendothelial space of the aortic valve.
The final experiment to test the importance of a stem cell niche to activate the cellular osteoblast gene program in the subendothelial layer cells was to test for the gene expression of the Wnt/Lrp5 pathway in the myofibroblast cells. The stem cell niche is a unique model for the development of an oxidative stress communication within the aortic valve endothelium. As shown in Figure 5, oxidative stress contributes to the release of Wnt3a into the subendothelial space to activate Lrp5/Frizzeled receptor complex on the extracellular membrane of the myofibroblast. This trimeric complex then induces glycogen synthase kinase to be phosphorylated. This phosphorylation event causes -catenin translocation to the nucleus. -catenin acts as a coactivator of osteoblast specific transcription factor Cbfa1 to induce mesenchymalosteoblastogenesis in the aortic valve myofibroblast cell.
Adult tissues stem cells are a population of functionally undifferentiated cells, capable of (i) homing (ii) proliferation, (iii) producing differentiated progeny, (iv) self-renewing, (v) regeneration, and (vi) reversibility in the use of these options. Within this definition, stem cells are defined by virtue of their functional potential and not by a specific observable characteristic. This data is the first to implicate a cell-cell communication between the aortic valve endothelial cell and the myofibroblast cell to activate the canonical Wnt pathway. Lrp5 is important in normal valve development [103], in this stem cell niche, reactivation of latent Lrp5 expression [5, 16], regulates osteoblastogenesis in these mesenchymal cells. The two corollary requirements necessary for an adult stem cell niche is to first define the physical architecture of the stem-cell niche and second is to define the gradient of proliferation to differentiation within the stem-cell niche. The aortic valve endothelial cell communicates with the myofibroblast cell to activate the myofibroblast to differentiate to form an osteoblast-like phenotype [14]. This concept is similar to the endothelial/mesenchymal transition critical in normal valve development [104]. This data fulfills these main corollaries of the plausibility of a stem cell niche responsible for the development of valvular heart disease. Within a stem cell niche there is a delicate balance between proliferation and differentiation. Cells near the stem-cell zone are more proliferative, and Wnt likely plays a role in directing cell differentiation. Stem cell behavior is determined by the number of its stem cell neighbors, which in the valve is the endothelial cell. This assumption is aimed at simply describing the fact that cytokines, secreted by cells into the micro-environment are capable of activating quiescent stem cells into differentiation [105].
The important inhibitor in this model is Notch1. Notch1 plays a roll in cellular differentiation decisions. In the osteoblast cell, it serves as an inhibitor of osteoblast differentiation [89, 90]. In the aortic valve, it serves to turn off bone formation via the cell-cell crosstalk between the endothelial and the myofibroblast cells. Normal Notch1 receptor functions to maintain normal valve cellular composition and homeostasis. In the presence of lipids, Notch1 is spliced and therefore activates osteoblastogenesis. In turn, the Wnt3a is secreted and binds to Lrp5 and Frizzled on the extracellular membrane to regulate the osteoblast gene program. This developmental disease process follows a parallel signaling pathway that has been observed in the normal embryonic valve development that has been well delineated by previous investigators [104]. A similar cell-cell communication is necessary for the development of valve disease.
This study provides the correlates described in the mathematical modeling by Agur [106]. This mathematical model has demonstrated the principal that the universal properties of the stem cells can be described in a simple discrete model as derived from hemopoietic stem cell behavior [106]. The transition of hemopoietic stem cells from quiescence into differentiation, is governed by their cell-cycling status, by stimulatory hormones secreted by neighboring cells into the micro-environment and by the level of amplification of stem-cell population [105, 107]. The model of Agur, defines the corollaries necessary to identify a stem cell niche, first the physical architecture of the stem cell niche and second the gradient necessary to regulate the niche. In the BAV the gradient is defined by the niche’s microenvironment. The initiation of event of oxidative stress inhibits normal endothelial nitric oxide synthase function, activates notch1 splicing which in turn induces Wnt3a secretion to activate bone formation within the valve [5, 17], [99].
The model proposed in the study as described in Figure 5, provides the cellular architecture for the development of this disease process. This model does not take into account other cytokine/growth factor mediated mechanisms that have been shown to also be important in this disease process [108]. However, understanding CAVD from a development disease perspective will provide a foundation for understanding this and other development disease processes. Clinical trials in the field of CAVD are demonstrating variable results [86, 87]. The possible differences in the published trials are secondary to the timing of therapy and the biological targeting of the lipid levels in these patients. Future medical therapies targeting stem cell niche mediated diseases provides a novel model system to test and to translate clinically for patients in the future.
References
- 1.
Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. Journal of the American College of Cardiology.Lindroos M. Kupari M. Heikkila J. Tilvis R. 1993 21 5 1220 1225 - 2.
Ross J. Jr Braunwald E. Aortic stenosis. Circulation 1968 Suppl):61 67 - 3.
Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. 2005 111 7 920 925 - 4.
Drolet M. C. Arsenault M. Couet J. Experimental aortic valve stenosis in rabbits. 2003 41 7 1211 1217 - 5.
Rajamannan N. M. Subramaniam M. Caira F. Stock S. R. Spelsberg T. C. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway 2005 Suppl):I229 234 - 6.
Rajamannan N. M. Subramaniam M. Springett M. Sebo T. C. Niekrasz M. Mc Connell J. P. Singh R. J. Stone N. J. Bonow R. O. Spelsberg T. C. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. 2002 105 22 2260 2265 - 7.
Weiss R. M. Ohashi M. JD Miller Young. S. G. Heistad D. D. Calcific aortic valve stenosis in old hypercholesterolemic mice. 2006 114 19 2065 2069 - 8.
Aikawa E. Nahrendorf M. Sosnovik D. Lok V. M. Jaffer F. A. Aikawa M. Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. 2007 115 3 377 386 - 9.
Rajamannan NM, Springett MJ, Pederson LG, Carmichael SW. Localization of caveolin 1 in aortic valve endothelial cells using antigen retrieval. Journal of Histochemistry&Cytochemistry.2002 50 5 617 628 - 10.
Rajamannan NM, Edwards WD, Spelsberg TC. Hypercholesterolemic aortic-valve disease. New England Journal of Medicine.2003 349 7 717 718 - 11.
Rajamannan N. M. Subramaniam M. Stock S. R. Stone N. J. Springett M. Ignatiev K. I. Mc Connell J. P. Singh R. J. Bonow R. O. Spelsberg T. C. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve Heart (British Cardiac Society).2005 91 6 806 810 - 12.
Makkena B. Salti H. Subramaniam M. Thennapan S. Bonow R. H. Caira F. Bonow R. O. Spelsberg T. C. Rajamannan N. M. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. 2005 45 4 631 633 - 13.
Rajamannan N. M. Sangiorgi G. Springett M. Arnold K. Mohacsi T. Spagnoli L. G. Edwards W. D. Tajik A. J. Schwartz R. S. Experimental hypercholesterolemia induces apoptosis in the aortic valve. Journal of Heart Valve Disease.2001 10 3 371 374 - 14.
Rajamannan N. M. Subramaniam M. Rickard D. Stock S. R. Donovan J. Springett M. Orszulak T. Fullerton D. A. Tajik A. J. Bonow R. O. Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. 2003 107 17 2181 2184 - 15.
Mohler E. R. 3rd Gannon F. Reynolds C. Zimmerman R. Keane M. G. Kaplan F. S. Bone formation and inflammation in cardiac valves. 2001 103 11 1522 1528 - 16.
Caira F. C. Stock S. R. Gleason T. G. Mc Gee E. C. Huang J. Bonow R. O. Spelsberg T. C. Mc Carthy P. M. Rahimtoola S. H. Rajamannan N. M. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation 2006 47 8 1707 1712 - 17.
The Journal of clinical investigation.Shao J. S. Cheng S. L. Pingsterhaus J. M. Charlton-Kachigian N. Loewy A. P. Towler D. A. Msx promotes. cardiovascular calcification. by activating. paracrine Wnt. signals 2005 115 5 1210 1220 - 18.
Desai M. Y. Rodriguez A. BA Wasserman Gerstenblith. G. Agarwal S. Kennedy M. Bluemke D. A. Lima J. A. Association of cholesterol subfractions and carotid lipid core measured by MRI. ArteriosclerThrombVasc Biol.2005 e110 111 - 19.
Subbaiah P. V. Gesquiere L. R. Wang K. Regulation of the selective uptake of cholesteryl esters from high density lipoproteins by sphingomyelin. J Lipid Res.2005 46 12 2699 2705 - 20.
BiochemBiophys Res Commun.Kim W. J. Chereshnev I. Gazdoiu M. Fallon J. T. Rollins B. J. Taubman M. B. M. C. P. deficiency is. associated with. reduced intimal. hyperplasia after. arterial injury. Biochem 2003 310 3 936 942 - 21.
Differential effects of the cyclin-dependent kinase inhibitorsTanner F. C. Boehm M. Akyurek L. M. San H. Yang Z. Y. Tashiro J. Nabel G. J. Nabel E. G. 27 Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation.2000 - 22.
Zhang R. Luo D. Miao R. Bai L. Ge Q. Sessa W. C. Min W. Hsp9 Akt phosphorylates. A. S. K. inhibits A. S. K1-mediated apoptosis. 2005 24 24 3954 3963 - 23.
4 91 1800 1809 Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. The Journal of clinical investigation. 1993;91(4):1800-1809 - 24.
Aikawa M. Rabkin E. Sugiyama S. Voglic S. J. Fukumoto Y. Furukawa Y. Shiomi M. Schoen F. J. Libby P. An-Co H. M. G. reductase A. inhibitor cerivastatin. suppresses growth. of macrophages. expressing matrix. metalloproteinases tissue factor. in vivo. in vitro. 2001 103 2 276 283 - 25.
Williams J. K. Sukhova G. K. Herrington D. M. Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. 1998 31 3 684 691 - 26.
Shyy J. Y. Chien S. Role of integrins in endothelial mechanosensing of shear stress. Circ Res.2002 91 9 769 775 - 27.
Laufs U. Liao J. K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. Journal of Biological Chemistry.1998 273 37 24266 24271 - 28.
Venema RC, Sayegh HS, Kent JD, Harrison DG. Identification, characterization, and comparison of the calmodulin-binding domains of the endothelial and inducible nitric oxide synthases. Journal of Biological Chemistry.1996 271 11 6435 6440 - 29.
Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmalcaveolae and impairs eNOS activation. J Biol Chem.Blair A. Shaul P. W. Yuhanna I. S. Conrad P. A. Smart E. J. 1999 274 45 32512 32519 - 30.
Smart EJ, Anderson RG. Alterations in membrane cholesterol that affect structure and function of caveolae. Methods Enzymol.2002 353 131 139 - 31.
Pritchard K. A. Ackerman A. W. Ou J. Curtis M. Smalley D. M. Fontana J. T. Stemerman M. B. Sessa W. C. Native low-density lipoprotein induces endothelial nitric oxide synthase dysfunction: role of heat shock protein 90 and caveolin-1. Free RadicBiol Med.2002 33 1 52 62 - 32.
Banka CL, Black AS, Dyer CA, Curtiss LK. THP-1 cells form foam cells in response to coculture with lipoproteins but not platelets. J Lipid Res.1991 32 1 35 43 - 33.
Curtiss LK, Dyer CA, Banka CL, Black AS. Platelet-mediated foam cell formation in atherosclerosis. Clin Invest Med.1990 13 4 189 195 - 34.
ArteriosclerThromb.Brand K. Banka C. L. Mackman N. Terkeltaub R. A. Fan S. T. Curtiss L. K. Oxidized L. D. L. enhances lipopolysaccharide-induced. tissue factor. expression in. human adherent. monocytes Arterioscler. 1994 14 5 790 797 - 35.
Leibovich S. J. Polverini P. J. Shepard H. M. Wiseman D. M. Shively V. Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. 1987 329 6140 630 632 - 36.
Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol.Leibovich S. J. Chen J. F. Pinhal-Enfield G. Belem P. C. Elson G. Rosania A. Ramanathan M. Montesinos C. Jacobson M. MA Schwarzschild Fink. J. S. Cronstein B. 2002 160 6 2231 2244 - 37.
Subramanian SV, Polikandriotis JA, Kelm RJ, Jr., David JJ, Orosz CG, Strauch AR. Induction of vascular smooth muscle alpha-actin gene transcription in transforming growth factor beta1-activated myofibroblasts mediated by dynamic interplay between the Pur repressor proteins and Sp1/Smadcoactivators. MolBiol Cell.2004 15 10 4532 4543 - 38.
Stewart B. F. Siscovick D. Lind B. K. Gardin J. M. Gottdiener J. S. Smith V. E. Kitzman D. W. Otto C. M. Clinical factors associated with calcific aortic valve disease Cardiovascular Health Study.1997 29 3 630 634 - 39.
Aronow W. S. Ahn C. Kronzon I. ME Goldman Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. American Journal of Cardiology.2001 88 6 693 695 - 40.
Thrombosis & Vascular Biology.O’Brien K. D. Reichenbach D. D. Marcovina S. M. Kuusisto J. CE Alpers Otto. C. M. Apolipoproteins B. (a accumulate E. in the. morphologically early. lesion of. ‘degenerative’ valvular. aortic stenosis. 1996 16 4 523 532 - 41.
Presence of oxidized low density lipoprotein in nonrheumaticstenotic aortic valves. ArteriosclerThrombVasc Biol.Olsson M. Thyberg J. Nilsson J. 1999 19 5 1218 1222 - 42.
Sprecher D. L. Schaefer E. J. Kent K. M. Gregg R. E. Zech L. A. Hoeg J. M. Mc Manus B. Roberts W. C. Brewer H. B. Jr Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. American Journal of Cardiology.1984 54 1 20 30 - 43.
O’Brien K. D. Kuusisto J. Reichenbach D. D. Ferguson M. Giachelli C. CE Alpers Otto. C. M. Osteopontin is expressed in human aortic valvular lesions. 1995 92 8 2163 2168 - 44.
Mohler E. R. 3rd Adam L. P. Mc Clelland P. Graham L. Hathaway D. R. Detection of osteopontin in calcified human aortic valves. Thrombosis & Vascular Biology.1997 17 3 547 552 - 45.
Osteopontin is expressed in human aortic valvular lesions. [comment]. Circulation.O’Brien K. D. Kuusisto J. Reichenbach D. D. Ferguson M. Giachelli C. CE Alpers Otto. C. M. 1995 92 8 2163 2168 - 46.
Whittaker P. Boughner D. R. Perkins D. G. Canham P. B. Quantitative structural analysis of collagen in chordae tendineae and its relation to floppy mitral valves and proteoglycan infiltration. British heart journal.1987 57 3 264 269 - 47.
Dis.Wooley C. F. Baker P. B. Kolibash A. J. Kilman J. W. Sparks E. A. Boudoulas H. The floppy. myxomatous mitral. valve mitral. valve prolapse. mitral regurgitation. Prog Cardiovasc. 1991 33 6 397 433 - 48.
Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements: an extracellular matrix and echocardiographic study. [see comment].Grande-Allen K. J. Borowski A. G. Troughton R. W. Houghtaling P. L. Dipaola N. R. Moravec C. S. Vesely I. Griffin B. P. 54 61 2005 Jan 2004. - 49.
Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading.Grande-Allen K. J. Calabro A. Gupta V. Wight T. N. Hascall V. C. Vesely I. 621 633 2004 Jul. - 50.
Jian B. Jones P. L. Li Q. Mohler E. R. 3rd Schoen F. J. Levy R. J. Matrix metalloproteinase. is associated. with-C tenascin. in calcific. aortic stenosis. 2001 159 1 321 327 - 51.
Cell.Ducy P. Zhang R. Geoffroy V. Ridall A. L. Karsenty G. Osf Cbfa transcriptional a. activator of. osteoblast differentiation. [see. comment] 1997 89 5 747 754 - 52.
Aubin J. E. Liu F. Malaval L. Gupta A. K. Osteoblast and chondroblast differentiation. 1995 Suppl):77S EOF 83S EOF - 53.
Robinson JA, Harris SA, Riggs BL, Spelsberg TC. Estrogen regulation of human osteoblastic cell proliferation and differentiation. 1997 138 7 2919 2927 - 54.
Spelsberg TC, Harris SA, Riggs BL. Immortalized osteoblast cell systems (new human fetal osteoblast systems). Calcif Tissue Int.1995 Suppl 1):S18 21 - 55.
Davies M. R. Lund R. J. Mathew S. Hruska K. A. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am SocNephrol.2005 16 4 917 928 - 56.
Davies MR, Lund R J, Hruska KA.BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am SocNephrol.2003 14 6 1559 1567 - 57.
Parhami F. Garfinkel A. Demer L. L. Role of lipids in osteoporosis. Thrombosis & Vascular Biology.2000 20 11 2346 2348 - 58.
Parhami F. Mody N. Gharavi N. Ballard A. J. Tintut Y. Demer L. L. Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells. Journal of Bone & Mineral Research.2002 17 11 1997 2003 - 59.
Parhami F. Morrow A. D. Balucan J. Leitinger N. Watson A. D. Tintut Y. Berliner J. A. Demer L. L. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. ArteriosclerThrombVasc Biol.1997 17 4 680 687 - 60.
Parhami F. Tintut Y. Beamer W. G. Gharavi N. Goodman W. Demer L. L. Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res.2001 16 1 182 188 - 61.
Jono S. MD Mc Kee Murry. CE Shioi A. Nishizawa Y. Mori K. Morii H. Giachelli C. M. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res.2000 E10 17 - 62.
Wada T. MD Mc Kee Steitz. S. Giachelli C. M. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. CircRes.1999 84 2 166 178 - 63.
Parhami F. Mody N. Gharavi N. Ballard A. J. Tintut Y. Demer L. L. Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells. J Bone Miner Res.2002 17 11 1997 2003 - 64.
Willert K. Nusse R. Beta-catenin a. key mediator. of Wnt. signaling 1998 8 1 95 102 - 65.
Behrens J. von Kries. J. P. Kuhl M. Bruhn L. Wedlich D. Grosschedl R. Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. 1996 382 6592 638 642 - 66.
Huber O. Korn R. Mc Laughlin J. Ohsugi M. Herrmann B. G. Kemler R. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev.1996 59 1 3 10 - 67.
Journal of Biological Chemistry.Holmen S. L. Salic A. Zylstra C. R. Kirschner M. W. Williams B. O. A. novel set. of-Frizzled Wnt. fusion proteins. identifies receptor. components that. activate beta-catenin-dependent. signaling 2002 277 38 34727 34735 - 68.
Revue Medicale de la Suisse Romande.Caverzasio J. [. Wnt L. R. P. new a. regulation osteoblastic. pathway involved. in reaching. peak bone. masses] 2004 124 2 81 82 - 69.
Kahler RA, Westendorf JJ. Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. Journal of Biological Chemistry.2003 278 14 11937 11944 - 70.
Glucocorticoids Inhibit the Transcriptional Activity of LEF/TCF in Differentiating Osteoblasts in a Glycogen Synthase Kinase-3{beta}-dependent and-independent Manner. J. Biol. Chem.Smith E. Frenkel B. 2005 280 3 2388 2394 - 71.
Wang HY, Malbon CC. Wnt signaling, Ca2+, and cyclic GMP: visualizing Frizzled functions. Science (New York, N.Y.2003 300 5625 1529 1530 - 72.
CA Gregory Perry. AS Reyes E. Conley A. Gunn W. G. Prockop D. J. Dkk-1-derived Synthetic Peptides and Lithium Chloride for the Control and Recovery of Adult Stem Cells from Bone Marrow. J. Biol. Chem.2005 280 3 2309 2323 - 73.
Yano F. Kugimiya F. Ohba S. Ikeda T. Chikuda H. Ogasawara T. Ogata N. Takato T. Nakamura K. Kawaguchi H. Chung U. I. The canonical Wnt signaling pathway promotes chondrocyte differentiation in a Sox9-dependent manner. BiochemBiophys Res Commun.2005 333 4 1300 1308 - 74.
Jian B. Narula N. Li Q. Y. Mohler E. R. 3rd Levy R. J. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg.2003 75 2 457 465 discussion 465-456. - 75.
Mohler E. R. 3rd Chawla M. K. Chang A. W. Vyavahare N. Levy R. J. Graham L. Gannon F. H. Identification and characterization of calcifying valve cells from human and canine aortic valves. Journal of Heart Valve Disease.1999 8 3 254 260 - 76.
Alkadhi H. Wildermuth S. Plass A. Bettex D. Baumert B. Leschka S. Desbiolles L. M. Marincek B. Boehm T. Aortic Stenosis. Comparative Evaluation. of 1. Detector Row. C. T. Echocardiography 2006 - 77.
AcadRadiol.MJ Budoff Takasu. J. Katz R. Mao S. Shavelle D. M. O’Brien K. D. Blumenthal R. S. Carr J. J. Kronmal R. Reproducibility of. C. T. measurements of. aortic valve. calcification mitral. annulus calcification. aortic wall. calcification in. the multi-ethnic. study of. atherosclerosis Acad. 2006 13 2 166 172 - 78.
Liu F. CA Coursey-Clarke Grahame. Sciacca C. Rozenshtein R. R. Homma A. Austin S. J. H. Aortic valve calcification as an incidental finding at CT of the elderly: severity and location as predictors of aortic stenosis. Am J Roentgenol.2006 186 2 342 349 - 79.
Boxt LM. CT of valvular heart disease. Int J Cardiovasc Imaging.2005 21 1 105 113 - 80.
Lancet.Shavelle D. M. Takasu J. MJ Budoff Mao. S. Zhao X. Q. O’Brien K. D. H. M. G. Co A. reductase inhibitor. (statin aortic valve. calcium. [comment] 2002 359 9312 1125 1126 - 81.
Atorvastatin Inhibits Hypercholesterolemia-Induced Calcification in the Aortic Valves via the Lrp5 Receptor Pathway. Circulation.Rajamannan N. M. Subramaniam M. Caira F. C. Stock S. R. Spelsberg T. C. 2005 In Press. - 82.
Steinmetz E. F. Buckley C. Shames M. L. Ennis T. L. Vanvickle-Chavez S. J. Mao D. Goeddel L. A. Hawkins C. J. Thompson R. W. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice Ann Surg.2005 241 1 92 101 - 83.
Aronow W. S. Ahn C. Kronzon I. ME Goldman Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol.2001 88 6 693 695 - 84.
Shavelle D. M. Takasu J. MJ Budoff Mao. S. Zhao X. Q. O’Brien K. D. H. M. G. Co A. reductase inhibitor. (statin aortic valve. calcium 2002 359 9312 1125 1126 - 85.
Rosenhek R. Rader F. Loho N. Gabriel H. Heger M. Klaar U. Schemper M. Binder T. Maurer G. Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. 2004 110 10 1291 1295 - 86.
Cowell S. J. Newby D. E. Prescott R. J. Bloomfield P. Reid J. Northridge D. B. Boon N. A. A. randomized trial. of intensive. lipid-lowering therapy. in calcific. aortic stenosis. 2005 352 23 2389 2397 - 87.
Moura L. M. Ramos S. F. Zamorano J. L. Barros I. M. Azevedo L. F. Rocha-Goncalves F. Rajamannan N. M. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis 2007 49 5 554 561 - 88.
Garg V. Muth A. N. Ransom J. F. Schluterman M. K. Barnes R. King I. N. Grossfeld P. D. Srivastava D. Mutations in. N. O. T. C. H. cause aortic. valve disease. 2005 437 7056 270 274 - 89.
Sciaudone M. Gazzerro E. Priest L. Delany A. M. Canalis E. Notch . impairs osteoblastic. cell differentiation. 2003 144 12 5631 5639 - 90.
J Biol Chem.Deregowski V. Gazzerro E. Priest L. Rydziel S. Canalis E. Notch . overexpression inhibits. osteoblastogenesis by. suppressing Wnt/beta-catenin. but not. bone morphogenetic. protein signaling. 2006 281 10 6203 6210 - 91.
Lee TC, Zhao YD, Courtman DW, Stewart DJ. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. 2000 101 20 2345 2348 - 92.
Rajamannan NM, Helgeson SC, Johnson CM. Anionic growth factor activity from cardiac valve endothelial cells: Partial purification and characterization. Clinical Research.1988 A. - 93.
Johnson CM, Hanson MN, Helgeson SC. Porcine cardiac valvularsubendothelial cells in culture: cell isolation and growth characteristics. J Mol Cell Cardiol.1987 19 12 1185 1193 - 94.
Osman L. Yacoub M. H. Latif N. Amrani M. Chester A. H. Role of human valve interstitial cells in valve calcification and their response to atorvastatin 2006 Suppl):I547 552 - 95.
Rajamannan NM. Oxidative-mechanical stress signals stem cell niche mediated Lrp5 osteogenesis in eNOS(-/-) null mice. Journal of cellular biochemistry.2012 - 96.
Johnson CM, Helgeson SC. Glycoproteins synthesized by cultured cardiac valve endothelial cells: unique absence of fibronectin production. BiochemBiophys Res Commun.1988 153 1 46 50 - 97.
Willert K. JD Brown Danenberg. E. Duncan A. W. Weissman I. L. Reya T. Yates J. R. 3rd Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. 2003 423 6938 448 452 - 98.
Tintut Y. Alfonso Z. Saini T. Radcliff K. Watson K. Bostrom K. Demer L. L. Multilineage potential of cells from the artery wall. 2003 108 20 2505 2510 - 99.
Wnt/beta-catenin signaling stimulates chondrogenic and inhibits adipogenic differentiation of pericytes: potential relevance to vascular disease? Circ Res.Kirton J. P. Crofts N. J. George S. J. Brennan K. Canfield A. E. 2007 101 6 581 589 - 100.
Garcia-Cardena G. Martasek P. BS Masters Skidd. P. M. Couet J. Li S. Lisanti M. P. Sessa W. C. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the noscaveolin binding domain in vivo. J Biol Chem.1997 272 41 25437 25440 - 101.
Garcia-Cardena G. Oh P. Liu J. Schnitzer J. E. Sessa W. C. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling ProcNatlAcadSci U S A.1996 93 13 6448 6453 - 102.
Feron O. Dessy C. Moniotte S. Desager J. P. Balligand J. L. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase J Clin Invest.1999 103 6 897 905 - 103.
Hurlstone A. F. Haramis A. P. Wienholds E. Begthel H. Korving J. Van Eeden F. Cuppen E. Zivkovic D. Plasterk R. H. Clevers H. The Wnt/beta-catenin pathway regulates cardiac valve formation. 2003 425 6958 633 637 - 104.
Paruchuri S. Yang J. H. Aikawa E. Melero-Martin J. M. Khan Z. A. Loukogeorgakis S. Schoen F. J. Bischoff J. Human pulmonary valve progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming growth factor-beta2. Circ Res.2006 99 8 861 869 - 105.
Concepts of hemopoietic cell amplification. Synergy, redundancy and pleiotropy of cytokines affecting the regulation of erythropoiesis. Leuk Lymphoma.de Haan G. Dontje B. Nijhof W. 1996 - 106.
Agur Z. Daniel Y. Ginosar Y. The universal properties of stem cells as pinpointed by a simple discrete model. J Math Biol.2002 44 1 79 86 - 107.
Veiby OP, Mikhail AA, Snodgrass HR. Growth factors and hematopoietic stem cells. HematolOncolClin North Am.1997 11 6 1173 1184 - 108.
O’Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). ArteriosclerThrombVasc Biol.2006 26 8 1721 1728